Loading
The three-tier system (favourable, intermediate, adverse) that decides how aggressively an adult with AML is treated and whether a transplant is recommended.
The European LeukemiaNet 2022 update classifies AML by genetics: favourable (t(8;21), inv(16), NPM1 without FLT3-ITD, bZIP in-frame CEBPA); intermediate (NPM1 with FLT3-ITD, FLT3-ITD without NPM1, t(9;11)); adverse (TP53, complex/monosomal karyotype, myelodysplasia-related mutations, KMT2A rearrangements other than t(9;11), inv(3), t(6;9)). FLT3-ITD allelic ratio was dropped in 2022 because FLT3 inhibitors changed the outlook. Companion ELN MRD recommendations define molecular and flow thresholds.
In plain words · NPM1 is the most common mutation in adult leukaemia. It moves a nuclear protein into the cytoplasm and, it turns out, makes the leukaemia dependent on menin.
Showing the target this term concerns: NPM1 mutation.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia.
Shares MRD-guided transplant decisions in intermediate-risk AML, IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia.
Shares FLT3-ITD allelic ratio, FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Myelodysplastic syndromes / neoplasms (MDS).
Shares NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.